CXCR4 and neoplasm: Inhibitors of the CXCR4–CXCL12 axis have been developed as a therapeutic approach considering the prognostic relevance of CXCR4 overexpression and the role of this axis in tumor growth (AMD3100/Plerixafor, Nox-A12 and others) [14,18,19].